Locations:
Multidisciplinary, proactive approach also improved discharge outcomes
Phase 1 Breakfree-2 trial reports good safety and efficacy at week 26
Inflammatory protein eotaxin-1 may be a marker of future cognitive decline
Therapists and physicians collaborate to get medically stable patients moving
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Designed for digitization, distance health, discovery and more
Combining customized care, research capabilities and flexibility for the future
Using the EMR to identify subtle symptoms at triage
Leading investigators outline a new roadmap for clinical trials and observational research
The selective D1/D5 dopamine agonist provides symptom relief and improves daily function.
Integrating behavioral health expertise into the management of complex neurological disorders
Advertisement
Advertisement
Search